ACCESSIBILITY STATEMENT

Our Commitment to Accessibility

GenTraceDx is committed to ensuring that our website, digital tools, and clinical resources are accessible to all users, including individuals with disabilities.
  • Effective Date: January 2026
  • Last Updated: January 2026
We aim to comply with:
  • WCAG 2.1 Level AA (Web Content Accessibility Guidelines)
  • AODA (Accessibility for Ontarians with Disabilities Act)
  • ADA (Americans with Disabilities Act)
  • Section 508 accessibility standards
  • Provincial and federal accessibility expectations in Canada

As a nationally funded precision oncology platform, accessibility is a core part of our mission to make innovative cancer diagnostics available to all patients, clinicians, and partners.

Who This Statement Applies To

This statement covers:

  • The GenTraceDx public website
  • Patient-facing information
  • Press & media pages
  • News articles
  • Educational materials
  • Clinician and researcher resources
  • Downloads (PDF, DOCX), wherever feasible
  • Multimedia content (videos & transcripts)

It does not cover:

  • Secure clinician portals (which follow separate clinical accessibility reviews)
  • Third-party systems linked externally

Accessibility Features

We have implemented multiple features to improve accessibility, including:
Screen reader compatibility
  • Proper use of ARIA labels
  • Logical heading hierarchy (H1 → H2 → H3)
  • Descriptive alt-text for all images
High-contrast text and color choices
  • Ensuring readability against backgrounds
  • Meeting WCAG contrast ratios
Keyboard navigability
  • Full navigation without a mouse
  • Focus indicators visible across the site  
Resizable text
  • Browser zoom support up to 200% without breaking layout
Captions & transcripts for videos
  • All launch videos
  • Clinical explainer videos
  • Documentaries
  • Audio interviews
Avoidance of flashing or disruptive animations
  • No seizure-inducing flashes
  • Smooth, gentle transitions
Consistent layout and navigation
  • Clear sections, menus, and breadcrumbs
  • Predictable page structure
Forms designed for accessibility
  • Labeled input fields
  • Logical tab ordering
  • Error messaging that is visible + screen-reader friendly

Areas We Are Actively Improving

GenTrace is an evolving platform. Accessibility improvements we are currently working on include:
  • Additional alt-text for complex scientific graphics
  • Providing large-print versions of certain PDFs
  • Ensuring mathematical or scientific notation is readable by assistive technologies
  • Providing tactile or audio-accessible materials upon request
  • Enhancing video audio descriptions for individuals with low vision

We welcome suggestions to improve accessibility further.

Requesting Assistance

If you experience any difficulty accessing GenTrace content due to a disability, we want to help.

Please contact us:

Accessibility Team
Email: accessibility@gentrace.com
Phone: XXX-XXX-XXXX

We will respond within 3–5 business days and work to provide the content in an accessible format.

Feedback & Suggestions

We welcome feedback from:

  • Patients
  • Clinicians
  • Individuals with disabilities
  • Advocacy groups
  • Accessibility consultants

If you have ideas to help us improve accessibility:

Email: accessibility@gentrace.com
Subject: Accessibility Feedback

Ongoing Review

We regularly:

  • Audit our website for accessibility compliance
  • Review new pages, videos, and downloadable materials
  • Train staff on digital accessibility best practices
  • Update this statement as our accessibility practices evolve

Our goal is to meet or exceed WCAG 2.1 AA standards across all public-facing materials.

Commitment to Inclusive Precision Oncology

Accessibility is not just a requirement — it aligns with our mission.

As Canada’s first multiomic, AI-powered living cancer diagnostic, GenTraceDx is committed to ensuring that every clinician, every patient, and every family can access our information and benefit from our platform.

Scroll to Top